期刊
DIGESTIVE DISEASES AND SCIENCES
卷 58, 期 5, 页码 1271-1281出版社
SPRINGER
DOI: 10.1007/s10620-012-2499-3
关键词
Abcb4 knockout; AT1R-blocker; Beta blocker; Sclerosing cholangitis; Fibrogenesis
资金
- Marga and Walter Boll Stiftung
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease leading to cirrhosis and cholangiocellular carcinoma. Inhibitors of the renin-angiotensin system or the sympathetic nervous system delay liver fibrogenesis in animal models. We investigated the antifibrotic potential of telmisartan, an angiotensin II type 1 receptor antagonist, and the beta-adrenoceptor blocker propranolol in the PSC-like Abcb4 knockout mouse model. Sixty-five Abcb4 (-/-) mice were treated with telmisartan for 3 or 5 months (T) and with telmisartan plus propranolol for 3, 5, or 8 months (TP), or for 2 or 5 months starting with a delay of 3 months (TP delayed). Liver hydroxyproline content, inflammation, fibrosis, and bile duct proliferation were assessed; fibrosis-related molecules were analyzed by real-time polymerase chain reaction and Western blotting. Compared to controls, telmisartan monotherapy had no significant influence on hydroxyproline; however, telmisartan plus propranolol reduced hydroxyproline (TP 3 months, p = 0.008), fibrosis score (TP 3 months and TP 8 months, p = 0.043 and p = 0.008, respectively; TP delayed 8 months, p < 0.0005), bile duct proliferation (TP 8 months and TP delayed 8 months, p = 0.006 and p < 0.0005, respectively), and procollagen alpha 1(I), endothelin-1, TIMP-1 and MMP3 mRNA as well as alpha-SMA, CK-19, and TIMP-1 protein. Telmisartan plus propranolol reduces liver fibrosis and bile duct proliferation in the PSC-like Abcb4 (-/-) mouse model, even when started at late stages of fibrosis, and may thus represent a novel therapeutic option for cholestatic liver diseases such as PSC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据